Superworth

Prelude Therapeutics EPS PRLD

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$0.74
Latest quarter, Q2 FY26
−$0.14
Fiscal year 2025
−$1.30

Prelude Therapeutics' earnings per share was −$0.74 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.14.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.30n/a
FY2024−$1.69n/a
FY2023−$2.05n/a
FY2022−$2.44n/a
FY2021−$2.41n/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.14n/a−$0.74
Q1 FY26−$0.13n/a−$1.01
Q4 FY25−$0.21n/a−$1.30
Q3 FY25−$0.26n/a−$1.47
Q2 FY25−$0.41n/a−$1.64
Q1 FY25−$0.42n/a−$1.69
Q4 FY24−$0.38n/a−$1.69
Q3 FY24−$0.43n/a−$1.79
Q2 FY24−$0.46n/a−$1.81
Q1 FY24−$0.42n/a−$1.89
Q4 FY23−$0.48n/a−$2.05
Q3 FY23−$0.45n/a−$2.17

Against its peers

Companies in Drug Manufacturers - General nearest Prelude Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
PRLDPrelude Therapeutics−$0.74
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
AMPHAmphastar Pharmaceuticals$1.70−36% a year
LFVNLifevantage$0.40−46% a year
Peer median$0.85

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Prelude Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.